Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

Article  PubMed  Google Scholar 

Bekaii-Saab T, Kim R, Kim TW, O’Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, et al. Third- or later-line therapy for metastatic colorectal cancer: reviewing best practice. Clin Colorectal Cancer. 2019;18(1):e117–29.

Article  PubMed  Google Scholar 

Zheng Y, Mislang ARA, Coward J, Cosman R, Cooper A, Underhill C, Zhu J, Xiong J, Jiang O, Wang H, et al. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunol Immunother. 2022;71(10):2371–9.

Article  PubMed  PubMed Central  Google Scholar 

Bever KM, Le DT. An expanding role for immunotherapy in colorectal cancer. J Natl Compr Canc Netw. 2017;15(3):401–10.

Article  PubMed  Google Scholar 

Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188447.

Article  PubMed  PubMed Central  Google Scholar 

Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, Long J, Zhang W, Yin F, Cai H, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–45.

Article  PubMed  PubMed Central  Google Scholar 

Gu Y, Wang J, Li K, Zhang L, Ren H, Guo L, Sai Y, Zhang W, Su W. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol. 2014;74(1):95–115.

Article  PubMed  Google Scholar 

Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319(24):2486–96.

Article  PubMed  PubMed Central  Google Scholar 

Sun L, Huang S, Li D, Mao Y, Wang Y, Wu J. Efficacy and safety of fruquintinib plus PD-1 inhibitors versus regorafenib plus PD-1 inhibitors in refractory microsatellite stable metastatic colorectal cancer. Front Oncol. 2021;11:754881.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Wei B, Gao J, Cai X, Xu L, Zhong H, Wang B, Sun Y, Guo W, Xu Q, et al. Combination of fruquintinib and anti-PD-1 for the treatment of colorectal cancer. J Immunol. 2020;205(10):2905–15.

Article  PubMed  Google Scholar 

Guo Y, Zhang W, Ying J, Zhang Y, Pan Y, Qiu W, Fan Q, Xu Q, Ma Y, Wang G, et al. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: the dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. Eur J Cancer. 2023;181:26–37.

Article  PubMed  Google Scholar 

Yang X, Yin X, Qu X, Guo G, Zeng Y, Liu W, Jagielski M, Liu Z, Zhou H. Efficacy, safety, and predictors of fruquintinib plus anti-programmed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study. J Gastrointest Oncol. 2023;14(6):2425–35.

Article  PubMed  PubMed Central  Google Scholar 

Gou M, Qian N, Zhang Y, Yan H, Si H, Wang Z, Dai G. Fruquintinib in combination with PD-1 inhibitors in patients with refractory non-MSI-H/pMMR metastatic colorectal cancer: a real-world study in China. Front Oncol. 2022;12:851756.

Article  PubMed  PubMed Central  Google Scholar 

Wang L, Geng H, Liu Y, Liu L, Chen Y, Wu F, Liu Z, Ling S, Wang Y, Zhou L (2023) Hot and cold tumors: immunological features and the therapeutic strategies. MedComm (2020) 4(5):e343.

Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365–86.

Article  PubMed  PubMed Central  Google Scholar 

Nuti M, Zizzari IG, Botticelli A, Rughetti A, Marchetti P. The ambitious role of anti angiogenesis molecules: turning a cold tumor into a hot one. Cancer Treat Rev. 2018;70:41–6.

Article  PubMed  Google Scholar 

Dai Y, Sun L, Zhuang L, Zhang M, Zou Y, Yuan X, Qiu H. Efficacy and safety of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer: a retrospective cohort study. J Gastrointest Oncol. 2022;13(2):722–31.

Article  PubMed  PubMed Central  Google Scholar 

Song Y, Qu T, Zhang H, Sun Y, Cui C, Chi Y, Zhang W, Wang X, Yang L. The real-world practice of fruquintinib for chinese patients with metastatic colorectal cancer. Cancer Manag Res. 2021;13:6199–205.

Article  PubMed  PubMed Central  Google Scholar 

Xiong L, He H, Fan M, Hu L, Wang F, Song X, Shi S, Qi B. Discovery of novel conjugates of quinoline and thiazolidinone urea as potential anti-colorectal cancer agent. J Enzyme Inhib Med Chem. 2022;37(1):2334–47.

Article  PubMed  PubMed Central  Google Scholar 

Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S, et al. Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature. 2017;545(7652):98–102.

Article  PubMed  PubMed Central  Google Scholar 

Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60.

Article  PubMed  PubMed Central  Google Scholar 

Nie C, Lv H, Chen B, Xu W, Wang J, Liu Y, Wang S, Zhao J, He Y, Chen X. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy: a real-world study. Front Oncol. 2022;12:917353.

Article  PubMed  PubMed Central  Google Scholar 

Deng YY, Zhang XY, Zhu PF, Lu HR, Liu Q, Pan SY, Chen ZL, Yang L. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: a real-world study. Front Oncol. 2023;13:1097911.

Article  PubMed  PubMed Central  Google Scholar 

Zhang W, Zhang Z, Lou S, Li D, Ma Z, Xue L. Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: a retrospective study. Front Oncol. 2022;12:929342.

Article  PubMed  PubMed Central  Google Scholar 

Stemmer A, Margalit O, Serpas V, Strauss G, Thomas J, Shah P, Tau N, Levanon K, Shacham-Shmueli E, Kopetz S, et al. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - outcome and novel predictive markers. Eur J Cancer. 2024;198:113495.

Article  PubMed  Google Scholar 

Saberzadeh-Ardestani B, Jones JC, McWilliams RR, Tougeron D, Halfdanarson TR, Guimbaud R, Hubbard JM, Flecchia C, Shi Q, Alouani E, et al. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting. Eur J Cancer. 2024;196:113433.

Article  PubMed  Google Scholar 

Fakih M, Wang C, Sandhu J, Ye J, Egelston C, Li X. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases. Eur J Cancer. 2024;196:113437.

Article  PubMed  Google Scholar 

Nukatsuka M, Fujioka A, Nagase H, Tanaka G, Hayashi H. Evaluation of a novel combination therapy, based on trifluridine/tipiracil and fruquintinib, against colorectal cancer. Chemotherapy. 2023;68(2):102–10.

Article  PubMed  Google Scholar 

Jin Y, Li J, Shen L, Xu J, Zhang Y, Zhang J, Pan H, Qu X, Chen Y, Zhang Q, et al. A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer. Front Oncol. 2022;12:1044328.

Article  PubMed  PubMed Central  Google Scholar